The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Shares in TripAdvisor (TRIP) were in the red in after hours trading after surging by 16% in Thursday's session as it was revealed by the Wall Street Journal that activist investor Starboard Value has ...

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer.

In early corporate news, AstraZeneca receives EU approval for a bladder cancer therapy, and a subdued housing market leaves MJ Gleeson eyeing adjusted pretax profit at the lower end of current market ...

It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.

-- AstraZeneca is in talks with Summit Therapeutics for a deal in which it could pay as much as $15 billion over time to license a lung-cancer drug, Bloomberg reported Thursday, citing people familiar ...